AGEN
Price:
$4.95
Market Cap:
$106.78M
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 m...[Read more]
Industry
Biotechnology
IPO Date
2000-02-08
Stock Exchange
NASDAQ
Ticker
AGEN
According to Agenus Inc.’s latest financial reports and current stock price. The company's current ROE is 122.08%. This represents a change of 276.30% compared to the average of 32.44% of the last 4 quarters.
The mean historical ROE of Agenus Inc. over the last ten years is 77.30%. The current 122.08% ROE has changed 57.92% with respect to the historical average. Over the past ten years (40 quarters), AGEN's ROE was at its highest in in the September 2021 quarter at 426.61%. The ROE was at its lowest in in the June 2022 quarter at -1496.02%.
Average
77.30%
Median
105.25%
Minimum
-274.96%
Maximum
443.09%
Discovering the peaks and valleys of Agenus Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 78.16%
Maximum Annual ROE = 443.09%
Minimum Annual Increase = -361.23%
Minimum Annual ROE = -274.96%
Year | ROE | Change |
---|---|---|
2023 | 153.28% | -65.41% |
2022 | 443.09% | -261.15% |
2021 | -274.96% | -333.21% |
2020 | 117.90% | 78.16% |
2019 | 66.18% | -28.53% |
2018 | 92.59% | -41.84% |
2017 | 159.19% | -50.95% |
2016 | 324.58% | -361.23% |
2015 | -124.25% | -32.68% |
2014 | -184.58% | -127.50% |
The current ROE of Agenus Inc. (AGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
107.14%
5-year avg
101.10%
10-year avg
77.30%
Agenus Inc.’s ROE is greater than Icosavax, Inc. (-41.24%), less than Galera Therapeutics, Inc. (21.95%), greater than Marker Therapeutics, Inc. (-78.91%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Adaptimmune Therapeutics plc (-117.47%), greater than Mereo BioPharma Group plc (-63.39%), greater than Pieris Pharmaceuticals, Inc. (-97.28%), greater than PDS Biotechnology Corporation (-137.06%), greater than Leap Therapeutics, Inc. (-98.01%), greater than Viking Therapeutics, Inc. (-15.05%), greater than TG Therapeutics, Inc. (-38.21%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than TCR2 Therapeutics Inc. (-89.51%), greater than Affimed N.V. (-155.57%), less than ADC Therapeutics SA (163.46%),
Company | ROE | Market cap |
---|---|---|
-41.24% | $769.04M | |
21.95% | $4.08M | |
-78.91% | $26.59M | |
-28.01% | $1.64B | |
-117.47% | $278.72M | |
-63.39% | $664.26M | |
-97.28% | $22.50M | |
-137.06% | $107.88M | |
-98.01% | $107.52M | |
-15.05% | $6.00B | |
-38.21% | $3.41B | |
32.93% | $109.78M | |
-95.61% | $5.30B | |
-89.51% | $58.11M | |
-155.57% | $57.26M | |
163.46% | $260.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agenus Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Agenus Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Agenus Inc.'s ROE?
How is the ROE calculated for Agenus Inc. (AGEN)?
What is the highest ROE for Agenus Inc. (AGEN)?
What is the 3-year average ROE for Agenus Inc. (AGEN)?
What is the 5-year average ROE for Agenus Inc. (AGEN)?
How does the current ROE for Agenus Inc. (AGEN) compare to its historical average?